Observation on the sedative effect of remidazolam combined with propofol in painless abortion surgery

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078611

Enrollment

Unknown

Registered

2023-12-13

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless abortion surgery

Interventions

Propofol group (P):Propofol

Low dose remidazolam combined with propofol group:Low dose remidazolam combined with propofol

High dose remidazolam combined with propofol group:High dose remidazolam combined with propofol

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age 18-45 years old, ASA Grade I-II, BMI18~30kg/m^2

Exclusion criteria

Exclusion criteria: Individuals who are allergic to benzodiazepines, sufentanil, or propofol, have a history of drug addiction, suffer from mental illness, neurological disorders, or cognitive impairment.

Design outcomes

Primary

Measure	Time frame
Sedation success rate;Burp inversion incidence rate;	—

Secondary

Measure	Time frame
Dosage of propofol;Wake-up time;Hypoxia incidence rate;The incidence of hypotension;The incidence of bradycardia;	—

Countries

China

Contacts

Public ContactWang Hui

Yichang Central People's Hospital

3351914386@qq.com+86 135 0720 6015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026